New insider activity at Protagonist Therapeutics ( (PTGX) ) has taken place on February 6, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Director William Waddill of Protagonist Therapeutics has executed a notable stock sale, offloading 20,000 shares in a transaction valued at $1,673,600. This move highlights a significant insider transaction in the company’s stock, drawing attention from investors tracking executive trading activity.
Recent Updates on PTGX stock
In the last 24 hours, Protagonist Therapeutics’ stock action has been driven largely by renewed optimism around its clinical pipeline and long‑term revenue potential, prompting at least one analyst to lift their price target. H.C. Wainwright cited the company’s proven track record in drug development and assigned meaningful probabilities of success to key programs, including PN‑8047, an IL‑4R antagonist, and early obesity candidates, reflecting growing confidence in portfolio execution rather than broader market factors. A fresh corporate update also highlighted that Protagonist now has two potential blockbuster drugs, icotrokinra and rusfertide, with NDAs submitted in 2025 for plaque psoriasis and polycythemia vera, respectively, plus multiple Phase 2 and 3 readouts expected across immunology, hematology, and obesity. The prospect of up to $1.2 billion in future sales milestones and substantial milestone and royalty economics from longstanding Johnson & Johnson and Takeda partnerships reinforces expectations for sizable non‑dilutive revenue streams and a strong cash runway, which together underpin the recent positive recalibration of analyst assumptions and support the stock’s recent strength.
Spark’s Take on PTGX Stock
According to Spark, TipRanks’ AI Analyst, PTGX is a Neutral.
The score is primarily supported by improving financial performance—especially strong cash flow and a turn to positive profitability—along with a constructive pipeline/partnership update. Offsetting these positives are weak technical momentum (below key moving averages with negative MACD) and a demanding valuation (very high P/E with no dividend yield support).
To see Spark’s full report on PTGX stock, click here.
More about Protagonist Therapeutics
YTD Price Performance: -7.64%
Average Trading Volume: 905,564
Technical Sentiment Signal: Buy
Current Market Cap: $5.21B